About ReNeuron
We are a leading, UK-based adult stem cell company. Our primary objective is the development of stem cell therapies targeting areas of significant unmet or poorly met medical need.
We have received regulatory approval to commence a ground-breaking Phase I clinical trial in the UK with our lead ReN001 stem cell therapy for disabled stroke patients. Patient recruitment for this trial will commence shortly. There are an estimated 50 million stroke survivors worldwide, approximately one half of which are left with permanent disabilities. The annual health and social costs of caring for these patients is estimated to be in excess of £5 billion in the UK and in excess of US$50 billion in the USA. In addition to our stroke programme, we are developing stem cell therapies for a number of other conditions, including peripheral arterial disease and diseases of the retina.
We have also developed a range of stem cell lines for non-therapeutic applications - our ReNcell® products for use in academic and commercial research. Our ReNcell®CX and ReNcell®VM neural cell lines are marketed worldwide under license by USA-based Millipore Corporation.
Our shares are traded on the London AIM market under the symbol RENE.L.
Top of page